These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 33302115)
21. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883 [TBL] [Abstract][Full Text] [Related]
22. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768 [TBL] [Abstract][Full Text] [Related]
23. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Bridge JA; Liu J; Qualman SJ; Suijkerbuijk R; Wenger G; Zhang J; Wan X; Baker KS; Sorensen P; Barr FG Genes Chromosomes Cancer; 2002 Mar; 33(3):310-21. PubMed ID: 11807989 [TBL] [Abstract][Full Text] [Related]
24. Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from intergroup rhabdomyosarcoma studies III and IV. Pappo AS; Meza JL; Donaldson SS; Wharam MD; Wiener ES; Qualman SJ; Maurer HM; Crist WM J Clin Oncol; 2003 Feb; 21(4):638-45. PubMed ID: 12586800 [TBL] [Abstract][Full Text] [Related]
25. Histopathological classification of childhood rhabdomyosarcomas: relationship with clinical parameters and prognosis. Wijnaendts LC; van der Linden JC; van Unnik AJ; Delemarre JF; Voute PA; Meijer CJ Hum Pathol; 1994 Sep; 25(9):900-7. PubMed ID: 8088765 [TBL] [Abstract][Full Text] [Related]
26. Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Routh JC; Dasgupta R; Chi YY; Shnorhavorian M; Tian J; Walterhouse DO; Breneman J; Wolden SL; Arndt CA; Hawkins DS; Rodeberg DA Int J Cancer; 2020 Dec; 147(11):3168-3176. PubMed ID: 32525556 [TBL] [Abstract][Full Text] [Related]
27. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125 [TBL] [Abstract][Full Text] [Related]
28. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373 [TBL] [Abstract][Full Text] [Related]
29. Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies. Schloemer NJ; Xue W; Qumseya A; Luo LY; Hiniker SM; Lautz TB; Rhee DS; Arnold MA; Venkatramani R Pediatr Blood Cancer; 2023 Dec; 70(12):e30701. PubMed ID: 37783659 [TBL] [Abstract][Full Text] [Related]
30. Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Crane JN; Xue W; Qumseya A; Gao Z; Arndt CAS; Donaldson SS; Harrison DJ; Hawkins DS; Linardic CM; Mascarenhas L; Meyer WH; Rodeberg DA; Rudzinski ER; Shulkin BL; Walterhouse DO; Venkatramani R; Weiss AR Pediatr Blood Cancer; 2022 Jun; 69(6):e29644. PubMed ID: 35253352 [TBL] [Abstract][Full Text] [Related]
31. Rhabdomyosarcoma of the urinary bladder in adults: predilection for alveolar morphology with anaplasia and significant morphologic overlap with small cell carcinoma. Paner GP; McKenney JK; Epstein JI; Amin MB Am J Surg Pathol; 2008 Jul; 32(7):1022-8. PubMed ID: 18469707 [TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174 [TBL] [Abstract][Full Text] [Related]
33. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563 [TBL] [Abstract][Full Text] [Related]
34. Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Rodeberg DA; Stoner JA; Garcia-Henriquez N; Randall RL; Spunt SL; Arndt CA; Kao S; Paidas CN; Million L; Hawkins DS Cancer; 2011 Jun; 117(11):2541-50. PubMed ID: 24048802 [TBL] [Abstract][Full Text] [Related]
35. Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis. Kilpatrick SE; Teot LA; Geisinger KR; Martin PL; Shumate DK; Zbieranski N; Russell GB; Fletcher CD Cancer; 1994 Dec; 74(12):3227-33. PubMed ID: 7526971 [TBL] [Abstract][Full Text] [Related]
36. Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. Milewski D; Jung H; Brown GT; Liu Y; Somerville B; Lisle C; Ladanyi M; Rudzinski ER; Choo-Wosoba H; Barkauskas DA; Lo T; Hall D; Linardic CM; Wei JS; Chou HC; Skapek SX; Venkatramani R; Bode PK; Steinberg SM; Zaki G; Kuznetsov IB; Hawkins DS; Shern JF; Collins J; Khan J Clin Cancer Res; 2023 Jan; 29(2):364-378. PubMed ID: 36346688 [TBL] [Abstract][Full Text] [Related]
37. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739 [TBL] [Abstract][Full Text] [Related]
38. Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group. Minn AY; Lyden ER; Anderson JR; Million L; Arndt CA; Brown K; Hawkins DS; Donaldson SS J Clin Oncol; 2010 Sep; 28(27):4228-32. PubMed ID: 20713850 [TBL] [Abstract][Full Text] [Related]
39. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group. Aye JM; Xue W; Palmer JD; Walterhouse DO; Arnold MA; Heaton TE; Venkatramani R Pediatr Blood Cancer; 2021 Apr; 68(4):e28914. PubMed ID: 33501771 [TBL] [Abstract][Full Text] [Related]
40. TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A Children's Oncology Group report. Fair D; Maese L; Chi YY; Li M; Hawkins DS; Venkatramani R; Rudzinski E; Parham D; Teot L; Malkin D; Plon SE; Li H; Sabo A; Lupo PJ; Schiffman JD Pediatr Blood Cancer; 2023 May; ():e30413. PubMed ID: 37194615 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]